Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Odulimomab

Drug Profile

Odulimomab

Alternative Names: 25.3; 25.3 monoclonal antibody; Anti-CD11a monoclonal antibody 25.3; Anti-LFA-1 monoclonal antibody; Antilfa

Latest Information Update: 22 Dec 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunotech
  • Developer Immunotech; Sanofi Genzyme
  • Class Monoclonal antibodies
  • Mechanism of Action CD11a antigen antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Graft-versus-host disease; Renal transplant rejection
  • Discontinued Delayed graft function

Most Recent Events

  • 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
  • 08 May 2003 Discontinued - Preclinical for Diabetes mellitus in Japan (Intraperitoneal)
  • 13 Dec 2000 SangStat has discontinued development of odulimomab for the transplant indication in Europe and North America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top